Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.
- DOI
- 10.1016/s2213-2600(25)00206-1
- Published
- 2025-07-30
- Container
- Lancet Respir Med
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-2600-25-00206-1,
title = {Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.},
author = {Mayer-Hamblett N and Kerper NR and Clancy JP and Davies JC and Taylor-Cousar JL and Donaldson SH and Bell SC and Jain R and Simmonds NJ and Mall MA and Goss CH and Rayment JH and Setiawan L and Pilewski JM.},
year = {2025},
journal = {Lancet Respir Med},
doi = {10.1016/s2213-2600(25)00206-1},
url = {https://doi.org/10.1016/s2213-2600(25)00206-1}
}RIS
TY - JOUR TI - Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials. AU - Mayer-Hamblett N AU - Kerper NR AU - Clancy JP AU - Davies JC AU - Taylor-Cousar JL AU - Donaldson SH AU - Bell SC AU - Jain R AU - Simmonds NJ AU - Mall MA AU - Goss CH AU - Rayment JH AU - Setiawan L AU - Pilewski JM. PY - 2025 JO - Lancet Respir Med DO - 10.1016/s2213-2600(25)00206-1 UR - https://doi.org/10.1016/s2213-2600(25)00206-1 ER -
APA
N, M., NR, K., JP, C., JC, D., JL, T., SH, D., SC, B., R, J., NJ, S., MA, M., CH, G., JH, R., L, S., & JM., P. (2025). Maximising opportunity for therapeutic success: sequential participation in cystic fibrosis nucleic acid-based therapy trials.. Lancet Respir Med. https://doi.org/10.1016/s2213-2600(25)00206-1
Source records
- europe-pmc · retrieved 2026-09-27T08:18:34.298Z